• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Tyrosine Kinase Inhibitor
    6 Drugs classified under this drug class

    All the Drug Class Drugs

    partial basket chart

    Tyrosine Kinase Inhibitor. Imatinib 100 mg, 400 mg.
    F.C. TABS: 20, 60 x 100 mg; 10, 30 x
    Doses of 400 mg or 600 mg should be
    admin. once dly., whereas a daily dose
    of 800 mg should be admin. as 400 mg
    ×2/d in the morn. and even.
    Tmt. of adult pts. and child. 3 yrs. of age
    and above with Ph+ chron. myeloid
    leukaemia (Ph+ -CML) in chron. phase
    accelerat. phase or blast crisis. Glivec is
    also indicat. for the tmt. of adult pts.s
    with Kit (CD117) posit. unresect. and/or
    metastat. malignant GI strom. tumour.
    (GIST). Also indicated for the tmt. of :
    Adult pts. with newly diagnosed
    Philadelphia chromos. posit. acute
    lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. Adult pts.
    with relapsed or refract. Ph + ALL as
    monother. Adult pts. with unresect.
    dermatofibrosarcoma protuberans
    (DFSP) and adult pts. with recurrent and/
    or metastat. DFSP who are not eligible
    for surg. Adult pts. with myelodyspiastic/
    myeloproliferative dis.(MDS/MPD) assoc.
    with PDGFR ( platelet - derived growth
    factor recept. ) gene re- arrangements.
    Adult pts. with hypereosinophilic syndr.
    (HES) and/or chronic eosinophilic
    leukaemia (CEL) who have the FIP1L1-
    PDGFRalfa fusion kinase (mutational
    analysis or FISH demonstration fo CHIC2
    allele deletion) and for pts. with HES and/
    or CEL who are FIP1L1-PDGFR alfa fusion
    kinase negative . Adult pts. with aggress.
    systemic mastocytosis (ASM) without the
    D816V c-kit mutation .Adjuvant tmt. of
    adult pts. follow. complete gross resec. of
    Kit (CD117) positive GIST.
    C/I: Hypersens.

    partial basket chart

    Tyrosine Kinase Inhibitor. Axitinib 1 mg, 5 mg.
    F.C. TAB: 28, 56, 60, 180 × 5, 1 mg.
    Recomm.  init.  oral dose is 5 mg ×2/d. approx.. 12 hrs.  apart with / without food should be swallow.  whole with a glass of water.
    If the pt.  vomits or misses a dose, an addit. dose should not be taken. The next prescribed dose should be taken at the usual time. See lit.
    Tmt. of advanc. RCC after fail. of one prior syst. therapy.
    C/I: Hypersens.

    partial basket chart

    Tyrosine Kinase Inhibitor. Ruxolitinib Phosphate 5 mg, 10 mg, 15 mg, 20 mg.
    TAB: blist.: 56, bottle.: 60×5, 15, 20mg
    Start. dose:
    MF: The recomm. start. dose : in is 15
    mg ×2/d for pts. with a plat. count
    between 100,000/mm 3 and 200,000/
    mm 3 and 20 mg ×2/d for pts. with a
    plat. count of >200,000/mm 3 .
    PV: The recomm. start. dose of is 10
    Limited inform. to recommend a start.
    dose for pts. with plat. count. between
    50,000/mm3 & <100,000/mm3.
    The max. recomm. start. dose in these
    pts. is 5 mg ×2/d and the pts. should be
    titrated cautious.
    Dose modific.
    Doses may be titrat. based on safety &
    efficacy. Tmt. should be discont. for
    plat. counts less than 50,000/mm3 or
    absolute neutrophil counts less than
    500/mm3. In PV, tmt. should also be
    interrupt. when haemoglobin is below
    8 g/dl. After recov. of blood count.
    above these levels, dosing may be
    re-started at 5 mg ×2/d and gradual.
    incr. based on careful. See. lit.
    Myelofibrosis (MF).
    Tmt. of dis.-related splenomeg.or sympt. in
    adult pts. with prim. MF (also known as chron. idiopath. MF), post polycythaem.
    vera myelofibrosis or post essential
    thrombocythaem. MF.
    Polycythaem. vera (PV).
    Tmt. of adult pts. with PV who are resist. to
    or intolerant of hydroxyurea.
    C/I: Hypersens.
    Preg. Lact.

    partial basket chart

    Tyrosine Kinase Inhibitor. Erlotinib 100 mg, 150 mg.
    TABS: 30 x 100 mg, 150 mg. Non-small
    cell lung cancer: 150 mg 1 x dly
    without food. Pancreat. cancer: 100 mg
    dly without food in comb. with
    First-line tmt. locally advanced/metastat.
    non-small cell lung cancer (NSCLC) with
    EGFR activat. mutats. Tmt. locally.
    advanced/metastat. NSCLC aft. fail. of at
    least one prior chemother. reg. Monother.
    for maint. tmt. pts with locally advanc./
    metastat. non-small cell lung cancer
    whose disease not progress. aft. 4 cycles of
    platinum-based first-line chemother. In
    comb. with gemcitabine for first-line tmt.
    with locally advanced, unresect./
    metastat. pancreat. cancer.
    C/I: Hypersens. to erlotinib or excips.

    partial basket chart

    Tyrosine Kinase Inhibitor. Nilotinib (HCl monohydrate) 150 mg, 200 mg.
    CAPS: 28, 40, 112, 120 x 200 mg, 28, 112
    x 150 mg.
    Newly diagn. Ph+ CML-CP: recomm.
    dose 300 mg x 2 dly.
    Pts. with Ph+ CML-CP and CML-AP
    resist./intoler. to at least 1 prior ther.
    incl. imatinib: recomm. dose 400 mg x
    2 dly. See lit.
    150 mg, 200 mg: Tmt. adult pts. with newly
    diagn. Ph+ CML in chron. phase.
    200 mg only: Tmt. of Ph+ CML in chron./
    acceler. phase in pts. resist. to/experienc.
    signif. toxicity dur. tmt. imatinib.
    C/I: Hypersens.

    partial basket chart

    Tyrosine Kinase Inhibitor. Lapatinib (as ditosylate monohydrate) 250 mg.
    F.C. TABS: 70. Adjust dose accord. to
    indicat. and medical condit. Dose must
    be taken once dly, at least 1 hr before or
    after food. See lit.
    In comb. with capecitabine, tmt. advanced/
    metastat. breast cancer whose tumors
    overexpress ErbB2 (HER2) who have
    received prior ther. incl. anthracycline,
    taxane and trastuzumab. In comb. with
    letrozole for tmt. postmenopaus. women
    with hormone recept. +ive metastat. breast
    cancer that overexpress. HER2 recept. for
    whom hormon. tmt. indicat. Tmt. in
    combinat. with aromatase inhib. has not
    been compared to trastuzumab-cont.
    chemother. reg. for tmt. metastat. breast
    C/I: Hypersens.